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Abstract
Background: The Escarval-Risk study aims to validate cardiovascular risk scales in patients with hypertension,
diabetes or dyslipidemia living in the Valencia Community, a European Mediterranean region, based on data from
an electronic health recording system comparing predicted events with observed during 5 years follow-up study.
Methods/Design: A cohort prospective 5 years follow-up study has been designed including 25000 patients with
hypertension, diabetes and/or dyslipidemia attended in usual clinical practice. All information is registered in a
unique electronic health recording system (ABUCASIS) that is the usual way to register clinical practice in the
Valencian Health System (primary and secondary care). The system covers about 95% of population (near 5 million
people). The system is linked with database of mortality register, hospital withdrawals, prescriptions and assurance
databases in which each individual have a unique identification number. Diagnoses in clinical practice are always
registered based on IDC-9. Occurrence of CV disease was the main outcomes of interest. Risk survival analysis
methods will be applied to estimate the cumulative incidence of developing CV events over time.
Discussion: The Escarval-Risk study will provide information to validate different cardiovascular risk scales in patients
with hypertension, diabetes or dyslipidemia from a low risk Mediterranean Region, the Valencia Community.
Background
Cardiovascular diseases (CVD) are the leading causes of
mortality (13%) and one of the most important producing
disability-associated living years (DALYs) (10%) in over de
world. Population research and public health surveillance
have made enormous contributions to the control of car-
diovascular diseases (CVD) over the last 50 years. In vir-
tually all industrialized countries the mortality from stroke
and heart disease has declined 50-70%. Much of this suc-
cess can be attributed to the identification of the underly-
ing causes of CVD that are embedded in contemporary
lifestyle. Despite the capacity of prevention, CVD are
considered an epidemic in Europe with over 4.3 million
deaths per year, accounting for the leading cause of death
[1]. CVD mortality and its trends vary within European
Regions and the Mediterranean area shows the lowest
mortality rates [1]. In these countries, the growth and pro-
gressive ageing of the population in recent years have led
to the paradoxical situation of reduced age-adjusted CHD
mortality on the background of an increased number of
deaths which tend to occur later in life and, consequently,
a greater burden of disease and disability [2]. In Spain, a
Mediterranean country, CVD is the leading cause of death
accounting for 122793 deaths with a standardized rate of
231/106Inhab in 2008 [3-5]. The Valencia Community, a
Spanish Mediterranean region located on the east-coast,
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with a population of 4885029, had CVD as the leading
cause of death too, accounting for 13241 deaths with a
standardized rate of 258/106Inhab in 2008, one of the
highest rates in Spain [3].
There is a large and compelling body of evidence on
the efficacy of primary CVD prevention [6], and of its
population impact. Risk scales (Frammingham, Score)
help clinicians to identify those patients to be selected for
intervention. Global coronary heart disease (CHD) risk
information given to patients seems to improve the accu-
racy of risk perception and may increase intent to initiate
CHD prevention among individuals at moderate to high
risk. The effect of global risk presentation on more
remote outcomes is less clear and seems to be related to
the intensity of accompanying interventions [7].
Scale uncertainties applying to different populations
that those of their origin leads to the necessity of valida-
tion in different countries, regions or specific group of
patients. In Spain this was done by using prevalence not
incidence [8] and one calibration [9] have been made.
Likewise, our group tried to validate the scales using
incidences but with only one year of follow-up [10,11].
ABUCASIS, an electronic centralized clinical record
system for primary and secondary ambulatory care was
started in Valencia Community in 2003. The electronic
health recording system (HER) of the whole population,
around 5 millions of individuals is an excellent tool to
initiate new studies about incidence of CVD and to vali-
date the CHD scales widely used in clinical practice.
The aim of this study is to provide information to vali-
date different cardiovascular risk scales and to analyze
associated factors in patients with hypertension, diabetes
or dyslipidemia from a low risk Mediterranean European
Region. Incidence of cardiovascular events will be com-
pared with expected events from the cardiovascular risk
scales.
Methods/Design
Design
Escarval means EStudio CARdiometabolico VALenciano.
The Escarval-Risk is a 5 years cohort (2007-2012) fol-
low-up study. The study accounts with the support of
Valencian Health Authorities, the universities of Valen-
cia and Miguel Hernandez Elche, and the scientific
societies of Valencian primary care physicians (Sociedad
Valenciana de Medicina de Familia i Comunitaria and
Sociedad Española de Médicos de Atención Primaria
Comunidad Valenciana). This project has been included
in the Valencia Cardiovascular Health Plan 2007-2012.
Setting
The sample will be recruited from the population
receiving healthcare from the Valencia Health Agency.
The Valencia Community is a Spanish Mediterranean
region located on the east-coast, with a population (year
2007) of 4,885,029, with 3,205,724 people older than
30 yr.
Study participants
The study sample was selected in a two-step process
that involved recruitment of clinicians and their outpati-
ents. Around 800 clinicians have been selected to parti-
cipate (family physicians and nurses) from the 23 Health
Departments which have started with the ABUCASIS
system. In order to stimulate involvement in ESCAR-
VAL-RISK, the Valencia Health Agency have incorpo-
rated the participation in the study into the governance
contract with the Health Departments, and linked it to
the existing system of economic incentives associated to
quality indexes.
Patients aged 30 years or older with at least one of the
following CVD risk factors: hypertension, diabetes melli-
tus and/or dyslipidemia who attended for routine con-
sultation with the participating clinicians have been
selected (Table 1 and Figure 1). Patients with a history
of a previous CVD event, that those defined as the out-
comes (for ex myocardial infarction, angina, stroke, or
transitory ischemic attack) were excluded, as well as
patients already participating in clinical trials.
This sample size would make it possible to detect a
relative risk of ≥ 1.2, estimating an exposed proportion
of 50% and a proportion of censured observations of
88.0%, with a security of 95% and a statistical power of
80%. The total study population will be 25,001 patients.
Table 2 shows the participating patients by sex, and age.
The percentage of participating patients among those
invited was 80.1%.
Study variables and methods of data collection
Table 3 includes a description of data collection meth-
ods and variables in the ESCARVAL-RISK study. Infor-
mation is collected prospectively from the ABUCASIS
the only way to register patient’s information. Diagnoses
are registered by using IDC-9. To be sure of the validity
of the principal variables (mortality, cardiovascular
events), those other database resources are used. Every
patient has a unique personal identification number
(PIN) for the health system, so there is a unique electro-
nic centralized clinical record per patient and the PIN
allow to link other resources of data (Figures 2,3,4).
At least one fasting blood sample is obtained every
year. Laboratory parameters are obtained from the Hos-
pital where the clinician usually referred it. In a 10%
random sample of all centers with participating physi-
cians underwent a site visit for data monitoring and
audit, to ensure data quality.
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Ethics
The study is conducted according to the standards of the
International Guidelines for Ethical Review of Epidemio-
logical Studies (Council for International Organizations
of Medical Sciences-CIOMS-Geneva, 1991) and the
recommendations of the Spanish Society of Epidemiology
about the review of ethical aspects of epidemiological
research. The ESCARVAL-RISK study has been reviewed
and approved by the Committee for Ethics and Clinical
Trials of the Center for Public Health Research (Comite
Table 1 Criteria to include patients in the ESCARVAL-RISK study
1. Age 30 years or older
2. Free of clinical cardiovascular disease
3. At least one of the following cardiovascular risk factors (as assessed from the most recent data in the clinical record or anthropometry for obesity)
a) Hypertension - Systolic blood pressure ≥ 140 mm Hg, or
- Diastolic blood pressure ≥ 90 mm Hg, or
- Under antihypertensive medication
b) Diabetes mellitus - Fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl), or
- Under antidiabetic medication (insulin or oral medications)
c) Dyslipidaemia - LDL cholesterol ≥ 4.1 mmol/l (160 mg/dl), or
- HDL cholesterol < 1.036 mmol/l (40 mg/dl) in men, and < 1.30 mmol/l (50 mg/dl) in women, or
- Triglycerides ≥ 1.7 mmol/l (150 mg/dl), or
- Under lipid-lowering medication.
4. Informed consent
Figure 1 Flow diagram of the Escarval-Risk study.
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Ético de Investigación Clínica (CEIC) de la Dirección
General de Salud Pública y Centro Superior de Investiga-
cion de Salud Pública (DGSP-CSISP)). The ESCARVAL-
RISK is a naturalistic, observational study undertaken as
part of routine clinical practice, with no special interven-
tions (except a training program for participating clini-
cians) to the patients included in the study. No additional
risks associated with participation are anticipated, as any
additional diagnosis, evaluation or treatment will be pro-
vided, apart from what the attending physician deems
appropriate.
Confidentiality of the data
All information relative to the patient’s identity is con-
sidered confidential. Patients’ data collected from the
ABUCASIS during the study will be documented anon-
ymously, making impossible to use this information to
identify the patients. The only link between the data
and the patient is a code used exclusively for this study,
in such a way that only the ABUCASIS system will be
able to associate the data to an identified or identifiable
individual. The data generated during the study will be
handled according the Law 5/1999 and corresponding
norms. All of the researchers with access to the data
used in the study will be required to sign a document
guaranteeing confidentiality.
Informed consent
Although the study does not involve the randomization
of the sample or the application of further interventions,
prior to inclusion, all patients must read the “Patient
Information Form” and sign a document giving consent.
Contact
There is a Technical Secretariat located at the Centro
Superior de Investigación en Salud Publica (CSISP),
Avda. Cataluña, 21, 46020 Valencia, Spain; mail: secre-
tariatecnica@escarval.info. Escarval-Risk is one of the
studies for a broader CVD research project called
ESCARVAL. More information could be found in
http://www.escarval.info/.
Statistical analysis
The main analyses will be conducted according to a sta-
tistical plan drafted before completion of data collection.
Statistical analyses will address the main study objec-
tives. Accordingly, CV observed risk will be calculated
and compared to expected risk according to CV risk
scales (Framingham, Score) [6].
For descriptive analysis the cut-points defining control
of each risk factor will be taken from the European
Guidelines on CVD prevention [6]; for estimates of dys-
lipidemia control based on LDL and non-HDL choles-
terol, we will use the cut-points agreed in the consensus
statement from the American Diabetes Association and
the American College of Cardiology Foundation [12].
The risk of CVD death will be calculated with the
SCORE equation using the SCORE equation for low-
risk regions [13]. The risk of CVD morbidity will be cal-
culated with the Framingham equation [14] and other
similar scales validated for Spanish population [8,9].
The primary outcome for this study will be the esti-
mation of the probability of CVD in the presence of
other competitive events. Cumulative incidence of cardi-
ovascular events will be analyzed by competing risk sur-
vival methods, where each subject is at risk of failure
from different causes.
Competing risk survival analysis methods will be
applied to estimate the cumulative incidence of develop-
ing CVD events over time [15]. This method allows for
the fact that a patient may experience an event which is
different from the event of interest. These events are
known as competing risk events, and may preclude the
onset of the event of interest, or may modify the prob-
ability of the onset of the event of interest. In particular,
a hypertensive patient may die without developing any
kind of CV disease. In a Kaplan-Meier estimation
Table 2 Participating patients by sex, and age
Hypertension
Age Group men women Total %
30-39 216 145 361 2.91
40-49 895 631 1526 12.31
50-59 1554 1265 2819 22.74
60-69 2126 1880 4006 32.32
70-79 1356 1467 2823 22.77
80 and more 350 511 861 6.95
Total 6497 5899 12396 100.00
Diabetes mellitus
Age Group men women Total %
30-39 101 77 178 2.81
40-49 465 230 695 10.96
50-59 910 552 1462 23.06
60-69 1295 808 2103 33.17
70-79 796 661 1457 22.98
80 and more 189 256 445 7.02
Total 3756 2584 6340 100.00
Dyslipidemia
Age Group men women Total %
30-39 295 240 535 5.50
40-49 906 601 1507 15.49
50-59 1288 1168 2456 25.24
60-69 1497 1468 2965 30.47
70-79 816 1014 1830 18.81
80 and more 153 284 437 4.49
Total 4955 4775 9730 100.00
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approach, these persons would be treated as censored
and would be eliminated from the risk set. This could
lead to misleading results, as it is based on the assump-
tion that censoring is “non-informative”, meaning that a
censored patient has the same risk of developing CVD
as those who have complete follow-up. This is not the
case in patients who die before without developing
CVD, as they are no longer at risk.
Cumulative incidence functions will be used to com-
pare the observed incidence of events with the predicted
ones. The cumulative incidence function regression
model of Fine and Gray will be used for multiple regres-
sion analyses [16]. Additionally, clinical relevance of dif-
ferent variables will be evaluated using the ARR
(Absolute Risk Reduction), RRR (Relative Risk
Reduction) and NNT (Number Needed to Treat) and
their 95% confidence intervals.
Discussion
CVD are the leading cause of death despite of the great
capacity for prevention so new studies are designed for
better understanding these issue and gain insights for
designing interventions to overcome the barriers pre-
venting implementation of CVD prevention in clinical
practice [17].
ESCARVAL-RISK study can provide relevant informa-
tion to validate CV risk scales in Mediterranean patients
with CV risk factors as hypertension, diabetes and/or
dyslipidemia. The information may improve the predic-
tion of CV risk in this specific population. Furthermore,
Table 3 Data collection methods and main study variables in ESCARVAL-RISK study
Collection method Variables
Mortality register, Hospital dropouts database,
electronic clinical record ICD diagnoses.
Cause of death (All, Cardiovascular or not) Cardiovascular
Morbidity:
ICD-9 codes
- Ischemic heart disease 402.9; 404.9, 410-414
- Stroke. 430-438, 444
- Peripheral Vascular Disease. 440.2, 443.8, 444, 445, 447.9
- Aortic aneurysm. 441
- Heart failure. 428, 398.91
- Atrial fibrillation. 427.3
- Chronic renal insufficiency. 585.5, 585.6, 588.88, 593.9
791.0
- Proteinuria.
- Essential hypertension. 401, 403, 404, 405, 405.1,
405.11, 405.19, 997, 997.91,
401.0, 401.1, 401.9
- Diabetes mellitus. 250.0, 250.4, 362.0, 583.81,
581.81, 250.6, 250.5
- Hypercholesterolemia/hyperlipidemia. 272.0, 272.2
- Metabolic syndrome. 277.7
- Overweight and obesity. 278
- Retinopathy. 362.0, 362.11, 362.12, 362.81,
362.82, 363.41, 362.83.
Electronic clinical record abstraction of patients’
characteristics or measurements performed on
patients during the medical visits
Patients’ demographic and psychosocial characteristics
Relevant family medical history: early cardiovascular event
CVD risk factors related to lifestyle (tobacco smoking, physical
activity)
Weight, height, waist and hip circumference, and blood
pressure, under standardized conditions. Left ventricular
hypertrophy (Cornell criteria). Microalbuminuria (30-300 mg/
g). Comorbidity
- Current medication: antihypertensives, statins and
other lipid-lowering drugs, oral
- antidiabetics, insulin, anticoagulants, aspirin, and
combination drug therapy
Laboratory results taken from the clinical record (most
recent blood data and physical examination during
the previous year)
Total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL
cholesterol, triglycerides, apolipoprotein B, blood pressure,
glucose, hemoglobine-A1c, creatinine, glomerular filtration
rate (MDRD), fibrinogen (mg/dl), uric acid.
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the study can provide a better assessment of CVD risk
factors control as well as therapeutic compliance or clin-
ical inertia [18].
The CV risk scales are widely used in primary care to
identify high risk patients, and this label (high risk) has
implications specially to decide when to initiate or not
pharmacological treatment. Nowadays, SCORE risk scale is
recommended by European and Spanish Scientific Socie-
ties to use in clinical practice [6,19]. It has been published
that these widely used scales (Framingham, Score) overesti-
mate high risk in Mediterranean populations [20,21], so we
could have many over treated patients. On the other hand,
if there are high risk patients that are not identified and
not treated, CVD could not be prevented in these patients.
So ESCARVAL-RISK will also create opportunities to
improve clinical practice in Mediterranean regions.
We had a comprehensive framework for physician
sampling in the Valencia Community as all of them are
working in the Public Health System that is universal
for all citizens. Every physician and nurse has a list of
patients (average 1600) for clinical practice. If one
patient changes to one physician to another we still
have the information for the events although the new
physician decides not to participate in the study.
The participation rate among invited clinicians was
very high. This high percentage is probably due to both,
the support of Valencian Health Authorities and the
local leadership of the researchers. The fact of partici-
pating in this study (Hawthorne effect) may slightly
overestimate the control of CVD risk factors and quality
of care in usual clinical practice.
Nevertheless, the large number of practitioners included,
the coverage of ABUCASIS electronic system, help for that
ESCARVAL-RISK study is likely to provide a good valida-
tion of the risk scales for this European Mediterranean
population and a comprehensive picture of the status of
 
 
 
 
 
Figure 2 Source of information for ESCARVAL-RISK study: ABUCASIS Clinical record system linked with health information databases.
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Inclusión in the
study
E
Figure 3 Source of information for ESCARVAL-RISK study: ABUCASIS Clinical record system: A patient’s record.
Follow up screen 
Figure 4 Source of information for ESCARVAL-RISK study: ABUCASIS Clinical record system: Patient’s follow up screen.
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primary CVD prevention. Blood samples have been ana-
lyzed with the same methods in reference hospital labora-
tories in the same region. The results are automatically
sent from the laboratory to the electronic clinical record
once validated and signed by the analyst. So all results are
included in the clinical record and it does not depend on
the criteria of the clinician that could register only the
results that were out of range infra estimating the normal
values.
Assessment of control of CVD risk factors is based on
objective measures (blood pressure readings, anthropo-
metry, and laboratory results) specifically obtained for
the ESCARVAL-RISK study. Thus, data quality in the
ESCARVAL-RISK study is likely to exceed that of stu-
dies relying solely on retrospective data abstraction from
clinical records and interviews.
The electronic ABUCASIS system for primary and sec-
ondary ambulatory care is an opportunity to initiate new
studies about how CV and other diseases are managed in
real clinical practice. It permits a new kind of data based
in whole population studies and opens a room for new
epidemiological studies and at last for improvement clini-
cal practice and for giving best care for patients. Other
study has been initiated about osteoporosis prevention
using the same design for the validation of a population-
based prediction scale for osteoporotic fracture: the
ESOSVAL-R study [22].
Finally, the ESCARVAL-RISK study will provide infor-
mation about the real incidence of CVD in the popula-
tion with hypertension, diabetes or dyslipidemia of the
Region of Valencia (which can be useful for other Medi-
terranean regions). And also will help knowing the real
weight of each risk factor for CVD in this context. Not
only will constitute a useful prognostic tool, when
further developed with research on cost-utility, it will
help establish efficient criteria to identify the level of
risk at which treatment should be initiated.
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